Clinical trials: Acquired Immune Deficiency Syndrome Virus
Substance Use Disorders, HIV/AIDS
Project Matter: Intervention to Improve HIV Self-care Among Men Who Have Sex With Men (MSM) With Substance Use Disorders
This study will implement a pilot randomized controlled trial (RCT, N=60) to assess the feasibility and acceptability a refined emotion regulation intervention designed to improve engagement in HIV-care among substance using HIV+…
- Conditions
- Substance Use Disorders, HIV/AIDS, Homosexuality, Male
- Trial name
- NCT03899220
- Testing
- Project Matter
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Cryptosporidiosis, HIV Infections
Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study
To evaluate the safety and efficacy of azithromycin in the treatment of intestinal cryptosporidial infection in AIDS patients.
- Trial name
- NCT00002082
- Testing
- Azithromycin
- Where
- 4 sites in United States
- Sponsor
- Pfizer
Uterine Cervical Neoplasms, HIV/AIDS
Screening Test Accuracy of Gynocular™, HR-HPV Testing, VIA for Detection of Cervical Neoplastic Lesions, in Women Living With HIV
Cervical cancer in HIV-positive women is largely preventable through regular screening. The World Health Organization (WHO) recommends cervical screening for HIV-positive women every three years.
- Trial name
- NCT03931083
- Testing
- Screening for CIN2+/HSIL
- Where
- Zambia
- Volunteers
- 450 people
- Sponsor
- University of Bern
Infection, Human Immunodeficiency Virus
A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects
An oral dose in healthy subjects to determine the relative bioavailabilty of BMS-626529 administered as BMS-663068
- Trial name
- NCT02859259
- Testing
- BMS-663068 (1 tablet at 600 mg), BMS-663068 (4 tablets at 150 mg each tablet)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Methamphetamine Abuse, HIV/AIDS
The Getting Off App for Methamphetamine-Using Gay and Bisexual Men
A commonly used manualized outpatient methamphetamine intervention for gay and bisexual men, "Getting Off," is being translated into a mobile phone application (i.e., app) available for download through common app marketplaces.
- Trial name
- NCT03884946
- Testing
- Getting Off App
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- Friends Research Institute, Inc.
Human Immunodeficiency Virus
Impact of Pre-ART Blood CD4+ T Cell Level on the Rectal Reservoir in Long-term HIV-1 Treated Men
Although combined antiretroviral therapy (cART) has dramatically improved quality of life and lifespan of HIV infected individuals, it still fails to eliminate viral reservoirs.
- Trial name
- VIRECT (NCT02526940)
- Testing
- rectal biopsies, Blood samples
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Pneumonia, Pneumococcal, Hiv
Prevention of Missed Opportunities for HIV Diagnosis by Promoting HIV Testing of Patients With Pneumococcal Pneumonia at Nice University Hospital (PneumoVIH)
According to usual practices, HIV testing should be performed for each patient diagnosed for pneumococcal pneumonia. Unfortunately, in 2018, only 27% of patients were tested for HIV following pneumococcal pneumonia in Nice…
- Trial name
- PneumoVIH (NCT04909268)
- Testing
- HIV testing
- Where
- France
- Volunteers
- 94 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Acquired Immunodeficiency Syndrome, HIV Infections
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir…
- Trial name
- NCT01565850
- Testing
- D/C/F/TAF, DRV, COBI
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 153 people
- Sponsor
- Gilead Sciences
HIV/AIDS
Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio
A low CD4/CD8 ratio is considered a surrogate marker of immunosenescence and is an independent predictor of non-AIDS-related morbidity and mortality.
- Trial name
- MeritRate (NCT03178084)
- Testing
- Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID, Efavirenz QD + Zidovudine/Lamivudine BID, Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD
- Volunteers
- 721 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
HIV Infections, Acquired Immunodeficiency Syndrome
Improving Uptake of Early Infant Diagnosis of HIV for the Prevention of Mother-to-child Transmission of HIV
Early accurate diagnosis is one of the first crucial steps in care for infants born to HIV-infected mothers. Early initiation of antiretroviral therapy (ART) relies upon early diagnosis and results in significant reductions in…
- Trial name
- SMS4PMTCT (NCT01433185)
- Testing
- Text message
- Where
- Kenya
- Volunteers
- 388 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV
Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients
The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.
- Trial name
- NCT02500849
- Testing
- SB-728mR-HSPC Infusion 3 days following busulfan conditioning
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Human Immunodeficiency Virus, Alcohol-Related Disorders
Project Khanya: Peer-Delivered Intervention to Improve HIV Medication Adherence and Substance Use in South Africa
The purpose of this study is to evaluate a stepped care behavioral intervention for HIV medication adherence and substance use ("Khanya") integrated into an HIV primary care setting in South Africa.
- Conditions
- Human Immunodeficiency Virus, Alcohol-Related Disorders, Drug Use, Substance Use
- Trial name
- NCT05933226
- Testing
- Khanya
- Where
- South Africa
- Volunteers
- 160 people
- Sponsor
- University of Maryland, College Park
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study of Trimetrexate Plus Leucovorin in Children With Pneumocystis Carinii Pneumonia
To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in pediatric patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening…
- Trial name
- NCT00002317
- Testing
- Trimetrexate glucuronate, Leucovorin calcium
- Where
- United States
- Sponsor
- U.S. Bioscience
Human Immunodeficiency Virus
The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis
This study aims to describe the proportion of participants with non-occupational post-exposure prophylaxis (NPEP) failure, defined as NPEP non-completion (including loss to follow-up) at week 4 or primary HIV infection at week 4…
- Trial name
- dPEP (NCT02211690)
- Testing
- dolutegravir 50 mg (one tablet daily), emtricitabine-tenofovir 300/200 mg (one tablet daily)
- Where
- 5 sites in Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Andrew Carr
HIV Infections, AIDS
DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy
The purpose of this study is to evaluate whether a therapy with an all once daily regimen of stavudine extended release (d4T XR), lamivudine (3TC), and efavirenz (EFV) leads to improved outcomes, as measured by viral load, CD4…
- Trial name
- NCT00116116
- Testing
- efavirenz, stavudine extended release, lamivudine
- Where
- 10 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Human Immunodeficiency Virus
Pharmacy-based Pre-exposure Prophylaxis
The proposed research will develop a culturally appropriate pharmacy pre-exposure prophylaxis (PrEP) delivery model for black men who have sex with men (BMSM) who live in high poverty, racial minority neighborhoods.
- Trial name
- NCT04393935
- Testing
- Pharmacy Delivered PrEP Intervention
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV/AIDS
Reaching 90% HIV Suppression: The Role of POC Viral Load Monitoring in Nigeria
The UNAIDS 90-90-90 goals represents an ambitious strategy to end the acquired immunodeficiency syndrome (AIDS) epidemic by 2020 [UNAIDS, 2015].
- Trial name
- POC (NCT03533868)
- Testing
- Point-of-care viral load monitoring test
- Where
- 2 sites in Nigeria
- Volunteers
- 543 people
- Sponsor
- Harvard School of Public Health (HSPH)
HIV/AIDS
Impact of Metformin on Immuno-virologic Parameters in HIV
Non-diabetic, aviremic HIV-infected individuals on antiretroviral therapy (ART) will be randomized to metformin therapy or to observation for 72 weeks.
- Trial name
- NCT04500678
- Testing
- Metformin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Hawaii
HIV Infections
A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients
To determine the proportion of patients whose plasma HIV-1 RNA level remains below a detectable level (less than 500/ml) after 24 weeks of study therapy with either 141W94 monotherapy or 141W94 plus zidovudine (ZDV) and…
- Trial name
- NCT00001085
- Testing
- Amprenavir, Lamivudine, Zidovudine
- Where
- 15 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Integrase Inhibitor (MK-0518) Viral Decay
The eradication of HIV by antiretroviral therapy has thus far been elusive. It has been consistently demonstrated that a pool of latently infected, resting CD4+ T cells persists in the majority of HIV-infected individuals…
- Trial name
- NCT00520897
- Testing
- Raltegravir (MK0518), Leukopheresis, Sigmoid Biopsy
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Canadian Immunodeficiency Research Collaborative
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.